Implementing PrEP for Women Who Inject Drugs

Launched by UNIVERSITY OF PENNSYLVANIA · Apr 29, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on improving access to a medication called pre-exposure prophylaxis (PrEP) for women who inject drugs, as they are at high risk of getting HIV. The study aims to understand the needs and experiences of these women, healthcare providers, and clinic leaders to find better ways to provide PrEP in primary care and reproductive health clinics. By making it easier for these women to receive PrEP, the goal is to help reduce the number of new HIV infections in this vulnerable group.

To be eligible for this study, clinics must have had at least 50 visits from women who inject drugs in the past year and have at least three healthcare providers who offer primary or reproductive health services. The clinic leadership must also be willing to take part in the study. Participants can expect to be involved in discussions that will help shape how PrEP is offered in their clinics, ultimately working towards better health outcomes for women who inject drugs. This trial is currently recruiting participants, and it highlights the important role of community input in improving healthcare services.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• To be included in the pilot test of Practice Facilitation, clinics must:
• • Complete prior leadership and provider surveys
• • Have 50 or more clinic visits with women who inject drugs in the past year
• • Have 3 or more clinicians who provide primary and/or reproductive healthcare
• • Have leadership willing to participate
• Exclusion Criteria:
• • None